Statistics indicate that the highest expenditure within the past five years via Aasandha coverage was on cases of Type 2 diabetes and hypertension.
In 2019, MVR 39.8 million was spent via Assandha on treatment of hypertension cases, with the number rising to MVR 78.7 million in 2020.